Donor Atorvastatin Treatment for Preventing Severe Acute Graft-Versus-Host Disease in Patients Undergoing Myeloablative Peripheral Blood Stem Cell Transplantation

Inclusion Criteria:

   - Human leukocyte antigen (HLA)-identical sibling donor

   - Myeloablative preparative regimen (i.e., >= TBI 12.0 Gy, >= busulfan (BU) 8.0 mg/kg
   PO, >= BU 6.4 mg/kg intravenously (IV), >= treosulfan 42 g/m^2 IV) according to
   investigational study or standard treatment plan; other "myeloablative" preparative
   regimens are acceptable as long as they are approved by the principal investigator or
   designee

   - Transplantation of PBSC

   - Cyclosporine (CSP)-based postgrafting immunosuppression

   - Willingness to give informed consent

   - DONOR: Age >= 18 years

   - DONOR: HLA genotypically identical sibling

   - DONOR: Willingness to give informed consent

Exclusion Criteria:

   - Nonmyeloablative preparative regimen

   - Participation in an investigational study that has acute GVHD as the primary endpoint

   - The allogeneic PBSC donor has a contraindication to statin treatment

   - DONOR: Age < 18 years

   - DONOR: Active liver disease (alanine aminotransferase [ALT] or aspartate
   aminotransferase [AST] levels > 2 times the upper limit of normal [ULN])

   - DONOR: History of myopathy

   - DONOR: Hypersensitivity to atorvastatin

   - DONOR: Pregnancy

   - DONOR: Nursing mother

   - DONOR: Current serious systemic illness

   - DONOR: Concurrent treatment with strong inhibitors of hepatic cytochrome P450 (CYP)
   3A4 (i.e. clarithromycin, erythromycin, protease inhibitors, azole antifungals)

   - DONOR: Current use of statin drug

   - DONOR: Failure to meet Fred Hutchinson Cancer Research Center (FHCRC) or local
   criteria for stem cell donation

   - DONOR: Total creatinine kinase > 2 times the ULN